Phase I/IIa Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety, tolerability, recommended phase II (RP2) dose, and efficacy
of Belantamab mafodotin for participants with Relapsed Refractory AL Amyloidosis (RRAL.)